Other: standard treatment (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01408732 (ClinicalTrials.gov) | February 2011 | 1/7/2011 | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Epistaxis;Hereditary Hemorrhagic Telangiectasia | Drug: Sclerotherapy;Other: Standard Treatment | University of Minnesota | American Rhinologic Society | Completed | 18 Years | N/A | All | 18 | Phase 1;Phase 2 | United States |